Charles Schwab Investment Management Inc Viridian Therapeutics, Inc.\De Transaction History

Charles Schwab Investment Management Inc

$557 Billion
Q2 2025

A detailed history of Charles Schwab Investment Management Inc transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 574,021 shares of VRDN stock, worth $13.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

574,021

Previous 565,963 1.42%

Holding current value

$13.8 Million

Previous $7.63 Million 5.18%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 12, 2025	BUY	$11.02 - $16.09 $88,799 - $129,653	8,058 Added 1.42%	574,021 $8.02 Million
Q1 2025 Sep 15, 2025	SELL	$13.48 - $20.91 $108,621 - $168,492	-8,058 Reduced 1.4%	565,963 $7.63 Million
Q1 2025 May 09, 2025	SELL	$13.48 - $20.91 $122,762 - $190,427	-9,107 Reduced 1.58%	565,963 $7.63 Million
Q4 2024 Feb 06, 2025	BUY	$17.85 - $25.71 $1.05 Million - $1.51 Million	58,857 Added 11.4%	575,070 $11 Million
Q3 2024 Nov 12, 2024	BUY	$12.16 - $23.33 $392,670 - $753,372	32,292 Added 6.67%	516,213 $11.7 Million
Q2 2024 Aug 12, 2024	BUY	$11.6 - $17.26 $694,097 - $1.03 Million	59,836 Added 14.11%	483,921 $6.3 Million
Q1 2024 May 08, 2024	BUY	$17.09 - $23.82 $901,907 - $1.26 Million	52,774 Added 14.21%	424,085 $7.43 Million
Q4 2023 Feb 06, 2024	BUY	$11.12 - $22.5 $646,005 - $1.31 Million	58,094 Added 18.55%	371,311 $8.09 Million
Q3 2023 Nov 08, 2023	BUY	$15.16 - $24.7 $2.99 Million - $4.88 Million	197,430 Added 170.51%	313,217 $4.8 Million
Q2 2023 Aug 09, 2023	BUY	$22.57 - $29.67 $264,452 - $347,643	11,717 Added 11.26%	115,787 $2.75 Million
Q1 2023 May 11, 2023	BUY	$25.04 - $37.6 $45,823 - $68,808	1,830 Added 1.79%	104,070 $2.65 Million
Q4 2022 Feb 13, 2023	BUY	$18.78 - $29.74 $538,816 - $853,270	28,691 Added 39.01%	102,240 $2.99 Million
Q3 2022 Nov 14, 2022	BUY	$10.7 - $25.5 $56,742 - $135,226	5,303 Added 7.77%	73,549 $1.51 Million
Q2 2022 Aug 15, 2022	BUY	$9.55 - $19.0 $651,749 - $1.3 Million	68,246 New	68,246 $790,000

Others Institutions Holding VRDN

# of Institutions

184

Shares Held

83.1M

Call Options Held

78.9K

Put Options Held

417K

View Full List

About Viridian Therapeutics, Inc.\DE

Ticker VRDN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,888,900
Market Cap $960M
Description
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...

More about VRDN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Viridian Therapeutics, Inc.\De Transaction History